Pfizer Net Cash Flow 2012-2026 | PFE
Pfizer annual/quarterly net cash flow history and growth rate from 2012 to 2026. Net cash flow can be defined as the total change in cash for the company over the given period.
- Pfizer net cash flow for the quarter ending March 31, 2026 was $287M, a 116.26% decline year-over-year.
- Pfizer net cash flow for the twelve months ending March 31, 2026 was $-0.560B, a 82.76% decline year-over-year.
- Pfizer annual net cash flow for 2024 was $-1.81B, a 173.94% decline from 2023.
- Pfizer annual net cash flow for 2023 was $2.448B, a 261.58% decline from 2022.
- Pfizer annual net cash flow for 2022 was $-1.515B, a 1052.83% decline from 2021.
|
Pfizer Annual Net Cash Flow (Millions of US $) |
|
|---|---|
| 2024 | $-1,810 |
| 2023 | $2,448 |
| 2022 | $-1,515 |
| 2021 | $159 |
| 2020 | $475 |
| 2019 | $125 |
| 2018 | $-205 |
| 2017 | $-1,235 |
| 2016 | $-1,041 |
| 2015 | $298 |
| 2014 | $1,160 |
| 2013 | $-7,898 |
| 2012 | $6,899 |
| 2011 | $1,447 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |